二氢嘧啶脱氢酶活性在食管癌化疗中的临床研究

Clinical study of dihydropyrimidine dehydrogenase activity on chemotherapy of esophageal carcinoma

目的探讨食管癌患者血二氢嘧啶脱氢酶(dihydropyrimidine dehydrogen-ase,DPD)活性与一般临床资料、毒副作用及疗效的相关性。方法采用高效液相色谱法(high performanceliquidchromatog-raphy,HPLC)测定81例食管癌患者化疗前血DPD活性,行DLF方案化疗,同时观察化疗不良反应和疗效。结果血DPD活性在食管癌患者中呈正态分布。其与患者的一般临床资料无相关性,P>0.05;与5-FU致恶心呕吐、骨髓抑制、腹泻、口腔黏膜炎和疲劳等有相关性,P<0.05;与化疗疗效没有相关性,r=-0.81,P=0.11。结论血DPD活性与5-FU相关毒性呈负相关,与一般临床资料及化疗疗效无相关性。

OBJECTIVE：To explore the relationship between DPD activity and the common clinical data, treatment response, adverse events in esophageal cancer patients, METHODS： The DPD activity in blood with e sophageal cancer 81 patients was detected by high-performance liquid chromatography （HPLC） before chemotherapy. The patients with esophageal carcinoma received DLF regimen. Treatment response and adverse events in the patients were assessed. RESULTS： The DPD activity in blood was normally distributed in esophageal cancer patients. The DPD activity in blood had no correlation with common clinical data of the patients, P〉0. 05. The 5-FU associated toxicities had a negative relationship with DPD activity in blood, P〈0. 05. The DPD activity in blood had no relation with treatment response, r=-0. 81, P=0.11. CONCLUSIONS： The DPD activity in blood negatively correlates with 5-FU associated toxieities. The DPD activity in blood does not correlates with common clinical data and treatment response in esophageal cancer patients.